UNSPSC 51314312: Acrivastine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314312 Acrivastine/pseudoephedrine (Commodity) shows minimal alignment between the code's nominal scope and actual state and local procurement activity. The recent opportunities block contains no solicitations for acrivastine/pseudoephedrine specifically; instead, the three posted opportunities target naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products broadly. The code appears to capture a narrow pharmaceutical product line, but state and local issuing bodies are currently procuring across much wider therapeutic and product categories. When a jurisdiction does seek pharmaceuticals or related health supplies, it typically issues the request through cooperative purchasing vehicles or health agency channels rather than discrete commodity-level solicitations tied to individual active pharmaceutical ingredients.

The geographic spread of recent activity centers on Florida (Seminole County's naloxone IFB posted in June 2026) and Texas (HHS Commission's RFI on direct-to-manufacturer prescriptions posted in April 2026), with multistate cooperative purchasing playing a significant role—the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic pharmaceuticals and OTC products posted in January 2026 serves participating state and local facilities across Minnesota, Oregon, and other member jurisdictions. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) seeks 1,900 units of naloxone annually with quarterly deliveries; the MMCAP RFP (S1070000015802, due March 26, 2026) establishes multiple-award contracts for generic pharmaceuticals through three authorized wholesalers. Vendors pursuing pharmaceutical supply under state and local codes at this tier should expect to work through established wholesale distribution channels, comply with cGMP and Drug Supply Chain Security Act requirements, and participate in cooperative purchasing agreements that aggregate demand across multiple jurisdictions.